Entera Bio (NASDAQ:ENTX) Stock Price Crosses Above 50-Day Moving Average – Should You Sell?

Posted by Francis Steltz on Oct 28th, 2026

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report)’s share price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $2.89 and traded as high as $3.13. Entera Bio shares last traded at $3.06, with a volume of 203,524 shares.

Analyst Upgrades and Downgrades

ENTX has been the topic of several recent analyst reports. UBS Group set a $9.00 target price on Entera Bio in a research note on Friday, September 18th. Cantor Fitzgerald began coverage on Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating for the company. Wall Street Zen raised Entera Bio to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, October 15th. Finally, Lifesci Capital began coverage on Entera Bio in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

Read Our Latest Stock Analysis on ENTX

Entera Bio Trading Up 7.0%

The stock’s fifty day moving average price is $2.89 and its 200 day moving average price is $1.89.

Entera Bio (NASDAQ:ENTX – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). On average, sell-side analysts forecast that Entera Bio Ltd. will post -0.40 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Seven Fleet Capital Management LP lifted its stake in Entera Bio Ltd. (NASDAQ:ENTX – Free Report) by 51.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 as of its most recent filing with the Securities & Exchange Commission. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.